Could a hot flash drug also lower breast cancer risk?
NCT ID NCT04821375
Summary
This small, early-stage study tested whether a 6-month course of a menopause drug (bazedoxifene plus estrogen) could change certain breast tissue markers linked to higher cancer risk. It involved 16 women aged 45-65 who were experiencing menopausal symptoms and had an increased risk for breast cancer. Researchers used breast MRIs and mammograms to see if the drug combination affected these risk-related markers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INCREASED RISK FOR DEVELOPMENT OF BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
Conditions
Explore the condition pages connected to this study.